Evidence map›Paper›PMID 41055572›Full record

ArticleStatistics in medicine2025

Estimating and Evaluating Counterfactual Prediction Models.

Christopher B Boyer, Issa J Dahabreh, Jon A Steingrimsson

Abstract read
In one paragraph

Article in Statistics in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Christopher B BoyerDepartment of Quantitative Health Sciences, Cleveland Clinic Research, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0002-1101-2045
Issa J DahabrehDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Jon A SteingrimssonDepartment of Biostatistics, Brown University School of Public Health, Providence, Rhode Island, USA.

Funding

Use of Registries, Claims and Health System Data to Enhance the Evaluation of Cardiovascular Therapies in Clinical TrialsR01HL136708 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Issa J. Dahabreh, Robert Yeh · 2017 to 2026
$6.9M
CVD Epidemiology Training Program in Behavior, the Environment and Global HealthT32HL098048 · NHLBI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Goodarz Danaei, ERIC B RIMM · 2009 to 2026
$6.9M
Methods for generalizing inferences from cluster randomized controlled trials to target populationsR01LM013616 · NLM · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI DAHABREH, ISSA J. · 2022 to 2025
$1.4M
NHLBI NIH HHS R01 HL136708NHLBI NIH HHS R01HL136708NHLBI NIH HHS T32 HL098048NIH HHS T32HL98048-10NLM NIH HHS R01 LM013616Patient-Centered Outcomes Research Institute ME-2021C2-22365U.S. National Library of Medicine R01LM013616
6 · The paper itself

Abstract

Counterfactual prediction methods are required when a model will be deployed in a setting where treatment policies differ from the setting where the model was developed, or when a model provides predictions under hypothetical interventions to support decision-making. However, estimating and evaluating counterfactual prediction models is challenging because, unlike traditional (factual) prediction, one does not observe the potential outcomes for all individuals under all treatment strategies of interest. Here, we discuss how to estimate a counterfactual prediction model, how to assess the model's performance, and how to perform model and tuning parameter selection. We provide identification and estimation results for counterfactual prediction models and for multiple measures of counterfactual model performance, including loss-based measures, the area under the receiver operating characteristic curve, and the calibration curve. Importantly, our results allow valid estimates of model performance under counterfactual intervention even if the candidate prediction model is misspecified, permitting a wider array of use cases. We illustrate these methods using simulation and apply them to the task of developing a statin-naïve risk prediction model for cardiovascular disease.

Indexed as

Models, StatisticalArea Under CurveCardiovascular DiseasesComputer SimulationHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRisk AssessmentROC CurveHydroxymethylglutaryl-CoA Reductase Inhibitorscausal inferencemachine learningmodel performanceprediction modeltransportabilitytreatment drop‐in

Identifiers

PMID41055572
PMCPMC12503020

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.